A Study Of The Effect Of Phosphodiesterease -5-Inhibitor On Serum Lipid Profile In The Male Rats

Abstract

Objective: Phosphodiesterease-5- (PDE-5) inhibitors now routinely recommended for erectile dysfunction treatment regimens but their effects on serum lipid are not well-understood. A significant number of patients receiving treatment for erectile dysfunction may have known or undiagnosed ischaemic heart disease, leading to considerable potential for adverse cardiovascular events. Moreover, many medications used for the treatment of cardiovascular disease may aggravate erectile dysfunction or complicate its treatment. This study was conducted to compare the effects of sildenafil, tadalafil and vardenafil on serum lipids.Setting: Department of Pharmacology, Kufa Medical College, Iraq.Methods: Forty-eight rats were divided into four groups of twelve rats each. Animals groups were fed a chow diet, sildenafil, tadalafil, and vardenafil respectively for six weeks. Lipid profiles at 0 week and 6 weeks were measured.Results: Control group showed non-significant (P>0.05) change in serum lipid profile. Sildenafil group showed significant (P<0.05) decrease in TG and TC, and non-significant (P>0.05) change in LDL-c and HDL-c.In tadalafil group, TC was highly significantly (P<0.01) decreased, while TG,LDL-c, HDL-c showed non-significant (P>0.05) change. In vardenafil group, there was no significant (P>0.05) change in TC, TG,HDL and LDL.Conclusion: Sildenafil may be considered a better erectile dysfunction therapy in dyslipidemia associated with erectile dysfunction as compared with tadalafil and vardenafil.